Business Wire

NEC

19.3.2021 03:02:08 CET | Business Wire | Press release

Share
NEC Qualifies 24 Fiber Pair Subsea Telecom Cable System

NEC Corporation (NEC; TOKYO: 6701) and its subsidiary OCC Corporation announced today that they have completed full qualification of subsea repeaters and optical cable containing up to 24 fiber pairs (FPs) (48 fibers). This is a 50% improvement in fiber count over the 16 fiber pair systems generally available today. This development allows cable owners worldwide to construct subsea telecom cables with superior traffic capacity while reducing the cost per bit of the wet plant. This approach is fully in line with SDM (Space Division Multiplexing) system architectures. NEC’s 24 FP solution not only provides more flexibility to operate in the subsea fiber pair market, it also enables better connectivity in high-density subsea branches.

NEC achieved this milestone with minor modifications to its proven repeater and cable designs. Keeping NEC’s quadruple pump redundancy in the repeater (established more than 10 years ago) and maintaining OCC’s outstanding cabling performance has resulted in cabled attenuations lower than 0.150dB/km. Low attenuation is critical to achieve large spectral efficiency as well as lower power consumption.

“As global demands for capacity and FP flexibility continue to soar, NEC is committed to helping our customers to build up their subsea networks with large spectral efficiency, lower power consumption and large-scale subsea connectivity,” said Yoshihisa Inada, Deputy General Manager and Head of Subsea Technology Development at NEC’s Submarine Network Division. “We continue to evaluate multiple technical options to further increase capacity and reduce the cost/bit of the networks.”

OCC’s 24 fiber pair cable can be manufactured using a wide range of existing optical fibers, according to the needs of each new cable system. Each fiber can be visually identified using a field-proven combination of ring marking and conventional fiber coloring, first introduced in 2013. Furthermore, in OCC cable, the fiber’s transmission performance is completely unaffected, either by the fiber marking or cabling processes.

“We have concluded that the use of our fibers in OCC’s 24 pair cable results in a cabled attenuation matching the nominal value. We are confident that our ultra-low-loss fibers can contribute to achieve large capacity, high spectral efficiency and low power consumption in transoceanic networks,” said Dr. Masashi Onishi, General Manager at Optical Fiber and Cable division of Sumitomo Electric Industries Ltd.

“To support growing bandwidth, next generation subsea systems will offer Petabit-scale transmission. To achieve the required performance, cabling processes must capture the advantaged optical attenuation and large effective area of our ultra-low-loss fibers. OCC’s cabling process for 24 fiber pairs works with our high quality fiber to meet the challenge,” said Dr. Bernhard Deutsch, VP & GM, Optical Fiber & Cable, Corning Incorporated.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

ProcureTEX Returns for Its Second Year, Bringing AI and Best-of-Breed Procurement Technology to Amsterdam14.10.2026 18:26:00 CEST | Press release

Founding partners Beroe, Keelvar and Zip bring back the community-driven event with a practitioner-shaped agenda spanning real-world AI use and the future of procurement ProcureTEX, the community-driven event for best-of-breed procurement technology, returns for its second year on November 3, 2026, at Circa in Amsterdam. Following its London debut in 2025, the event sharpens its focus on how AI is reshaping procurement. It will bring together over 250 procurement leaders and digital transformation teams from large enterprises, with vetted best-of-breed technology providers, to see AI agents and interoperable tools working together on real enterprise challenges. Co-founded by Beroe, Keelvar and Zip, the event is built on the belief that the future of procurement isn’t a monolithic all-in-one suite, but an ecosystem of best-of-breed tools working together. It is designed for procurement and enterprise leaders seeking scalable, modern solutions, whether they’re driving transformation, fru

eM Client 11 Launches: A European Outlook Alternative Bringing AI Freedom, Digital Sovereignty, and Next-Generation Productivity14.10.2026 18:16:00 CEST | Press release

eM Client, the European developer of the popular email and productivity application used by millions worldwide, today announced the release of eM Client 11, its most significant update yet. The new version introduces advanced AI capabilities, and major productivity improvements, strengthening its position as an independent alternative to Microsoft Outlook. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014945464/en/ eM Client 11 main window AI Without Vendor Lock-In eM Client 11 introduces a powerful AI Assistant that enables users to search, summarize, organize, and manage emails using natural language. Additional features include personalized AI writing, context-aware quick replies, automatic task and event detection, and AI-powered email rules. Unlike traditional AI integrations, eM Client 11 supports Bring Your Own Key (BYOK), allowing organizations to connect compatible AI providers and models of their choice. The re

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye